Skip to main content
. 2023 Jul 19;23(3):239–244. doi: 10.1007/s40268-023-00429-3
Apatinib had limited efficacy in the treatment of recurrent glioblastoma, and the adverse effects should also be paid attention to.
Moreover, significant individual variations were observed in its response.